ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC
Journal of Thoracic Oncology
◽
10.1016/j.jtho.2021.08.015
◽
2021
◽
Vol 16
(11)
◽
pp. 1793-1797
Author(s):
Sophie Stock-Martineau
◽
Frances A. Shepherd
Keyword(s):
Tyrosine Kinase
◽
Tyrosine Kinase Inhibitor
◽
Kinase Inhibitor
◽
Line Treatment
◽
First Line
◽
Egfr Tyrosine Kinase Inhibitor
◽
Egfr Tyrosine Kinase
◽
Egfr Mutant
◽
First Line Treatment
Download Full-text
Related Documents
Cited By
References
Dacomitinib (PF-00299804), An Irreversible Pan-Her Tyrosine Kinase Inhibitor (TKI), For First-Line Treatment of EGFR-Mutant or Her2-Mutant or -Amplified Lung Cancers
Annals of Oncology
◽
10.1016/s0923-7534(20)33849-7
◽
2012
◽
Vol 23
◽
pp. ix400-ix401
◽
Cited By ~ 1
Author(s):
M. Kris
◽
Z. Goldberg
◽
P.A. Janne
◽
D. Kim
◽
R. Martins
◽
...
Keyword(s):
Tyrosine Kinase
◽
Tyrosine Kinase Inhibitor
◽
Kinase Inhibitor
◽
Line Treatment
◽
First Line
◽
Lung Cancers
◽
Egfr Mutant
◽
First Line Treatment
Download Full-text
P3.01-073 TPX-0005 with an EGFR Tyrosine Kinase Inhibitor (TKI) Overcomes Innate Resistance in EGFR Mutant NSCLC
Journal of Thoracic Oncology
◽
10.1016/j.jtho.2017.09.1514
◽
2017
◽
Vol 12
(11)
◽
pp. S2230
Author(s):
R. Rosell
◽
N. Karachaliou
◽
J.J. Cui
◽
I. Chaib
◽
J. Berenguer
◽
...
Keyword(s):
Tyrosine Kinase
◽
Tyrosine Kinase Inhibitor
◽
Kinase Inhibitor
◽
Egfr Tyrosine Kinase Inhibitor
◽
Innate Resistance
◽
Egfr Tyrosine Kinase
◽
Egfr Mutant
Download Full-text
Survival‑associated factors of first‑line EGFR‑tyrosine kinase inhibitor responders and non‑responders in lung adenocarcinoma patients with common EGFR mutations
Molecular and Clinical Oncology
◽
10.3892/mco.2018.1550
◽
2018
◽
Author(s):
Ming‑Szu Hung
◽
Yu‑Hung Fang
◽
Yu‑Ching Lin
◽
Jr‑Hau Lung
◽
Meng‑Jer Hsieh
◽
...
Keyword(s):
Tyrosine Kinase
◽
Lung Adenocarcinoma
◽
Tyrosine Kinase Inhibitor
◽
Associated Factors
◽
Kinase Inhibitor
◽
Egfr Mutations
◽
First Line
◽
Egfr Tyrosine Kinase Inhibitor
◽
Egfr Tyrosine Kinase
Download Full-text
First-in-human phase I study of PF-06747775, a third-generation mutant selective EGFR tyrosine kinase inhibitor (TKI) in metastatic EGFR mutant NSCLC after progression on a first-line EGFR TKI
Annals of Oncology
◽
10.1093/annonc/mdx380.060
◽
2017
◽
Vol 28
◽
pp. v485-v486
◽
Cited By ~ 4
Author(s):
H. Husain
◽
R.G. Martins
◽
S.B. Goldberg
◽
P. Senico
◽
W. Ma
◽
...
Keyword(s):
Tyrosine Kinase
◽
Phase I
◽
Tyrosine Kinase Inhibitor
◽
Phase I Study
◽
Kinase Inhibitor
◽
Third Generation
◽
First Line
◽
Egfr Tyrosine Kinase Inhibitor
◽
Egfr Mutant
◽
Egfr Tki
Download Full-text
Imatinib—A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015
JAMA Oncology
◽
10.1001/jamaoncol.2015.50
◽
2015
◽
Vol 1
(2)
◽
pp. 143
◽
Cited By ~ 9
Author(s):
Carlo Gambacorti-Passerini
◽
Rocco Piazza
Keyword(s):
Chronic Myeloid Leukemia
◽
Tyrosine Kinase
◽
Tyrosine Kinase Inhibitor
◽
Myeloid Leukemia
◽
Kinase Inhibitor
◽
Line Treatment
◽
First Line
◽
First Line Treatment
Download Full-text
Targeting c-Myc to overcome acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR tyrosine kinase inhibitor, osimertinib
Cancer Research
◽
10.1158/0008-5472.can-21-0556
◽
2021
◽
pp. canres.0556.2021
Author(s):
Lei Zhu
◽
Zhen Chen
◽
Hongjing Zang
◽
Songqing Fan
◽
Jiajia Gu
◽
...
Keyword(s):
Tyrosine Kinase
◽
Tyrosine Kinase Inhibitor
◽
Kinase Inhibitor
◽
Acquired Resistance
◽
Third Generation
◽
Egfr Tyrosine Kinase Inhibitor
◽
The Third
◽
Egfr Tyrosine Kinase
◽
Egfr Mutant
Download Full-text
Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma
OncoTargets and Therapy
◽
10.2147/ott.s62639
◽
2014
◽
pp. 799
◽
Cited By ~ 9
Author(s):
Jeng-Sen Tseng
◽
Tsung-Ying Yang
◽
Kun-Chieh Chen
◽
Kuo-Hsuan Hsu
◽
Chong-Jen Yu
◽
...
Keyword(s):
Tyrosine Kinase
◽
Lung Adenocarcinoma
◽
Tyrosine Kinase Inhibitor
◽
Kinase Inhibitor
◽
Inhibitor Therapy
◽
Egfr Tyrosine Kinase Inhibitor
◽
Egfr Tyrosine Kinase
◽
Tyrosine Kinase Inhibitor Therapy
◽
Egfr Mutant
Download Full-text
Reduced chemotherapy sensitivity in EGFR-mutant lung cancer patient with frontline EGFR tyrosine kinase inhibitor
Lung Cancer
◽
10.1016/j.lungcan.2014.09.008
◽
2014
◽
Vol 86
(2)
◽
pp. 219-224
◽
Cited By ~ 10
Author(s):
Zhu Zeng
◽
Hong-hong Yan
◽
Xu-chao Zhang
◽
Wen-zhao Zhong
◽
Yan-yan He
◽
...
Keyword(s):
Lung Cancer
◽
Cancer Patient
◽
Tyrosine Kinase
◽
Tyrosine Kinase Inhibitor
◽
Lung Cancer Patient
◽
Kinase Inhibitor
◽
Egfr Tyrosine Kinase Inhibitor
◽
Chemotherapy Sensitivity
◽
Egfr Tyrosine Kinase
◽
Egfr Mutant
Download Full-text
P1.01-96 US Real-World Management of EGFR-Mutated Advanced NSCLC: Survival After First-Line EGFR-Tyrosine Kinase Inhibitor Treatment
Journal of Thoracic Oncology
◽
10.1016/j.jtho.2019.08.811
◽
2019
◽
Vol 14
(10)
◽
pp. S398-S399
Author(s):
J. Nieva
◽
K. Reckamp
◽
A. Taylor
◽
B. Thakrar
◽
J. Wong
◽
...
Keyword(s):
Tyrosine Kinase
◽
Tyrosine Kinase Inhibitor
◽
Real World
◽
Advanced Nsclc
◽
Kinase Inhibitor
◽
First Line
◽
Egfr Tyrosine Kinase Inhibitor
◽
Egfr Tyrosine Kinase
◽
Egfr Mutated
◽
Inhibitor Treatment
Download Full-text
Active or Attractive? Oral Antiangiogenesis Therapy Plus EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant NSCLC
Journal of Thoracic Oncology
◽
10.1016/j.jtho.2021.06.028
◽
2021
◽
Vol 16
(9)
◽
pp. 1426-1428
Author(s):
Bin-Chi Liao
◽
James Chih-Hsin Yang
Keyword(s):
Tyrosine Kinase
◽
Tyrosine Kinase Inhibitor
◽
Kinase Inhibitor
◽
Egfr Tyrosine Kinase Inhibitor
◽
Egfr Tyrosine Kinase
◽
Antiangiogenesis Therapy
◽
Egfr Mutant
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close